NPHC — Nutra Pharma Share Price
Last trade - 00:00- $0.76m
- $8.85m
- $0.10m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.07 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -592.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.12 | 0.13 | 0.1 | 0.05 | 0.1 | n/a | n/a | -10.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company's drug candidates include RPI-MN and RPI-78M. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin and Pet Pain-Away. Its pain relief categories include arthritis pain, chronic back pain, headaches and migraines, and knee and joint pain. Its over the counter (OTC) homeopathic products include Nyloxin Topical Gel, Extra Strength Nyloxin Topical Gel, Nyloxin Oral Spray, Extra Strength Nyloxin Oral Spray, Nyloxin Topical Gel Roll On, Nyloxin Professional Size Pump Topical Gel and Pet Pain Away. The Company's holds approximately 21 patents in their portfolio.
Directors
- Rik Deitsch CHM (47)
- Dale Vanderputten CSO (57)
- Stewart Lonky DRC (68)
- Garry Pottruck DRC (58)
- Harold Rumph DRC (84)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- February 1st, 2000
- Public Since
- October 9th, 2001
- No. of Shareholders
- 288
- No. of Employees
- 4
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 7,596,852,214
- Address
- 1537 NW 65th Avenue, PLANTATION, 33313
- Web
- https://www.nutrapharma.com/
- Phone
- +1 9545090911
- Auditors
- Rotenberg Meril Solomon Bertiger & Guttilla, P.C.
Upcoming Events for NPHC
Similar to NPHC
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 22:23 UTC, shares in Nutra Pharma are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Nutra Pharma last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Nutra Pharma share price has underperformed the S&P500 Index by -6.57% over the past year.
There is no consensus recommendation for this security.
Find out moreNutra Pharma does not currently pay a dividend.
Nutra Pharma does not currently pay a dividend.
Nutra Pharma does not currently pay a dividend.
To buy shares in Nutra Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Nutra Pharma had a market capitalisation of $0.76m.
Here are the trading details for Nutra Pharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NPHC
Based on an overall assessment of its quality, value and momentum Nutra Pharma is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nutra Pharma. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $0.00, shares in Nutra Pharma were trading +7.85% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nutra Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nutra Pharma's management team is headed by:
- Rik Deitsch - CHM
- Dale Vanderputten - CSO
- Stewart Lonky - DRC
- Garry Pottruck - DRC
- Harold Rumph - DRC